Latin America PoC Infectious Disease Testing Market Growth & Trends

The Latin America PoC infectious disease testing market size is expected to reach USD 1.1 billion by 2030 and is projected to grow at a CAGR of 2.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. This is driven by several key factors, including high disease prevalence, advancements in diagnostic technology, and supportive regulatory and governmental initiatives. The region continues to face a high burden of infectious diseases such as malaria, tuberculosis (TB), HIV, and neglected tropical diseases. According to the Pan American Health Organization (PAHO), diseases like dengue fever, Zika virus, and Chagas disease are endemic in LATAM, significantly impacting public health and creating a persistent demand for effective diagnostic tools.

Recent developments in diagnostic technology have also played a crucial role. Innovations such as rapid diagnostic tests (RDTs) and molecular assays have enhanced the speed and accuracy of disease detection. For instance, advances in CRISPR-based diagnostics and next-generation sequencing are improving the sensitivity of tests, which is crucial for managing infectious disease outbreaks and providing timely treatment.

Government and international initiatives further drive market growth. In response to the high disease burden, Latin American governments and organizations are implementing strategic health programs. The Brazilian Ministry of Health’s "Healthy Brazil" initiative and Colombia’s Disease Elimination Initiative are notable examples. These programs focus on improving disease control measures and expanding diagnostic capabilities. Additionally, international organizations like the Global Fund and PAHO are providing financial support and technical assistance, bolstering the infrastructure for disease testing and management.

Latin America PoC Infectious Disease Testing Market Report Highlights

  • Based on type, the PoC rapid diagnostic single test segment dominated the market with more than 70% of revenue share in 2023, driven by its practicality and effectiveness.
  • Based on disease, the COVID-19 segment dominated the market and accounted for 45.8% of the total share in 2023. This dominance is primarily driven by several factors, including the continued impact of the pandemic, high testing demand, and significant advancements in diagnostic technology.
  • Based on end use, the clinics segment held the largest share of 37.5% in 2023. Clinics are pivotal in providing primary healthcare services, including diagnostic testing for infectious diseases.
  • In May 2024, BioPerfectus received approval from Brazil’s ANVISA for its dengue and malaria diagnostic kits. In collaboration with the China CDC, the company developed the Malaria Pf/Pan (HRP2/pLDH) Antigen Rapid Test Kit, supplied to Papua New Guinea, to support local efforts in managing infectious diseases.